Preparation, nano purification, quality control and labeling optimization of [64Cu]-5,10,15,20-tetrakis (penta fluoro phenyl) porphyrin complex as a possible imaging agent

Fazaeli, Yousef; Jalilian, Amir Reza; Amini, Mostafa M.; Aboudzadeh, Mohammadreza; Feizi, Shahzad; Rahiminezhad, Ali; Yousefi, Kamran

doi:10.1007/s10967-012-1885-9

Cited by 29 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the results showed most of the 64 Cu activity within the kidneys and liver, with low uptake in tumor 170 . Similar effects were found in studies with other Cu-64 labeled PSs such as 64 Cu-5,10,15,20-tetrakis(penta fluoro phenyl) porphyrin, 64 Cu-labeled tri and tetra sulphonated phthalocyanines 171 , 172 . Rong et al, developed HPPH loaded PEG-functionalized graphene oxide (GO), forming GO-PEG-HPPH complex.…”

Section: Theranostics: ''Multifunctional Agents'' For Image-guided Photodynamic Therapysupporting

confidence: 82%

Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer

2021

View full text Add to dashboard Cite

In recent years tremendous effort has been invested in the field of cancer diagnosis and treatment with an overall goal of improving cancer management, therapeutic outcome, patient survival, and quality of life. Photodynamic Therapy (PDT), which works on the principle of light-induced activation of photosensitizers (PS) leading to Reactive Oxygen Species (ROS) mediated cancer cell killing has received increased attention as a promising alternative to overcome several limitations of conventional cancer therapies. Compared to conventional therapies, PDT offers the advantages of selectivity, minimal invasiveness, localized treatment, and spatio-temporal control which minimizes the overall therapeutic side effects and can be repeated as needed without interfering with other treatments and inducing treatment resistance. Overall PDT efficacy requires proper planning of various parameters like localization and concentration of PS at the tumor site, light dose, oxygen concentration and heterogeneity of the tumor microenvironment, which can be achieved with advanced imaging techniques. Consequently, there has been tremendous interest in the rationale design of PS formulations to exploit their theranostic potential to unleash the imperative contribution of medical imaging in the context of successful PDT outcomes. Further, recent advances in PS formulations as activatable phototheranostic agents have shown promising potential for finely controlled imaging-guided PDT due to their propensity to specifically turning on diagnostic signals simultaneously with photodynamic effects in response to the tumor-specific stimuli. In this review, we have summarized the recent progress in the development of PS-based multifunctional theranostic agents for biomedical applications in multimodal imaging combined with PDT. We also present the role of different imaging modalities; magnetic resonance, optical, nuclear, acoustic, and photoacoustic in improving the pre-and post-PDT effects. We anticipate that the information presented in this review will encourage future development and design of PSs for improved image-guided PDT for cancer treatment.

show abstract

Section: Theranostics: ''Multifunctional Agents'' For Image-guided Photodynamic Therapysupporting

confidence: 82%

Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer

2021

View full text Add to dashboard Cite

show abstract

“…Biodistribution studies on these various metal‐labelled species showed minimal variation between metals with uptake dominated by the porphyrin species. Exchange of TPP for the more polar 5,10,15,20‐tetrakis(pentafluorophenyl) porphyrin, labelled with 68 Ga or 64 Cu led to enhanced renal excretion . Similarly, early work by Robinson et al .…”

Section: Tetraphenylporphyrin Labellingmentioning

confidence: 79%

Radiolabelled porphyrins in nuclear medicine

Waghorn

2013

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Amongst tumour-specific substances, hematoporphyrin and synthetic porphyrin derivatives have been widely investigated to identify and delineate neoplastic and malignant tissue. Whilst the tumour localization exhibited by selected porphyrin species has been exploited through photodynamic therapy, several examples of porphyrin derivatives with varied peripheral functionality have been radiolabelled with the aim of developing porphyrin-based nuclear imaging and therapeutic agents. In this review, we look at the approaches and advances in the preparation and uses of such radiolabelled agents for imaging and therapy.

show abstract

“…Porphyrins are also being used as imaging agents in medical imaging systems. 6 , 53 - 55 Cationic porphyrins interact with DNA in various modes. Three major modes of interaction between porphyrins and DNA are intercalation, outside binding without self-stacking, and outside binding with self-stacking along the DNA surface.…”

Section: Introductionmentioning

confidence: 99%

Kinetics and mechanism of formation of nickel(II)porphyrin and its interaction with DNA in aqueous medium

et al. 2021

View full text Add to dashboard Cite

Graphic abstract Kinetics between 5,10,15,20-tetrakis(N-methylpyridium-4-yl)porphyrin and Ni 2+ species were investigated in aqueous solution at 25 ±1 °C in I = 0.10 M (NaNO 3 ). Speciation of Ni 2+ was done in I = 0.10 M (NaNO 3 ) for knowing distribution of Ni 2+ species with solution pH. Experimental data were compared with speciation diagram constructed from the values of hydrolysis constants of Ni 2+ ion. Speciation data showed that hexaaquanickel(II) ions took place in hydrolysis reactions through formation of [Ni(OH 2 ) 6-n (OH) n ] 2-n species with solution pH. According to speciation of Ni 2+ and pH dependent rate constants, rate expression can be written as: d[Ni(TMPyP) 4+ ]/dt = ( k 1 [Ni 2+ (aq) ] + k 2 [Ni(OH) + (aq) ] + k 3 [Ni(OH) 2 o (aq) ] + k 4 [Ni(OH) 3 - (aq) ])[H 2 TMPyP 4+ ], where k 1 , k 2 , k 3 and k 4 were found to be k 1 = (0.62 ± 0.22) × 10 -2 ; k 2 = (3.60 ± 0.40) × 10 -2 ; k 3 = (2.09 ± 0.52) × 10 -2 , k 4 = (0.53 ± 0.04) × 10 -2 M -1 s -1 at 25 ±1 °C, respectively. Formation of hydrogen bonding between [Ni(H 2 O) 5 (OH)] + and [H 2 TMPyP] 4+ causes enhanced reactivity. Rate of formation of [Ni(II)TMPyP] 4+ complex was to be 3.99 × 10 -2 M -1 s -1 in I = 0.10 M, NaNO 3 (25 ± 1 °C). UV-Vis and fluorescence data suggested that [Ni(II)TMPyP] 4+ and [H 2 (TMPyP)] 4+ interact with DNA via outside binding with self-stacking and intercalation, respectively. SYNOPSIS Kinetics of tetrakis(1-methylpyridium-4-yl)porphyrin with Ni 2+ were studied in aqueous medium at 25 ±1 °C in ...

show abstract

Preparation, nano purification, quality control and labeling optimization of [64Cu]-5,10,15,20-tetrakis (penta fluoro phenyl) porphyrin complex as a possible imaging agent

Cited by 29 publications

References 18 publications

Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer

Recent Advances in Photosensitizers as Multifunctional Theranostic Agents for Imaging-Guided Photodynamic Therapy of Cancer

Radiolabelled porphyrins in nuclear medicine

Kinetics and mechanism of formation of nickel(II)porphyrin and its interaction with DNA in aqueous medium

Contact Info

Product

Resources

About